Myocardial infarction and future risk of cancer in the general population—the Tromsø Study
- 327 Downloads
The association between myocardial infarction (MI) and future risk of incident cancer is scarcely investigated. Therefore, we aimed to study the risk of cancer after a first time MI in a large cohort recruited from a general population. Participants in a large population-based study without a previous history of MI or cancer (n = 28,763) were included and followed from baseline to date of cancer, death, migration or study end. Crude incidence rates (IRs) and hazard ratios (HRs) for cancer after MI were calculated. During a median follow-up of 15.7 years, 1747 subjects developed incident MI, and of these, 146 suffered from a subsequent cancer. In the multivariable-adjusted model (adjusted for age, sex, BMI, systolic blood pressure, diabetes mellitus, HDL cholesterol, smoking, physical activity and education level), MI patients had 46% (HR 1.46; 95% CI: 1.21–1.77) higher hazard ratio of cancer compared to those without MI. The increased cancer incidence was highest during the first 6 months after the MI, with a 2.2-fold higher HR (2.15; 95% CI: 1.29–3.58) compared with subjects without MI. After a 2-year period without higher incidence rate, MI patients displayed 60% (HR 1.60; 95% CI: 1.27–2.03) higher HR of future cancer more than 3 years after the event. The increased IRs were higher in women than men. Patients with MI had a higher short- and long-term incidence rate of cancer compared to subjects without MI. Our findings suggest that occult cancer and shared risk factors of MI and cancer may partly explain the association.
KeywordsMyocardial infarction Cancer Epidemiology Risk factors
The study has used data from the Cancer Registry of Norway. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Cancer Registry of Norway is intended nor should be inferred. K.G. Jebsen TREC is supported by an independent grant from the K.G. Jebsen Foundation.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 15.The Norwegian Institute of Public Health. Overweight and obesity in Norway: fact sheet. http://www.fhi.no/eway/default.aspx?pid=240&trg=List_6673&Main_6664=6894:0:25,7585:1:0:0:::0:0&MainContent_6894=6671:0:25,7612:1:0:0:::0:0&List_6673=6674:0:25,7616:1:0:0:::0:0. Accessed 26 Feb 2015.
- 16.WHO MONICA Project. MONICA Manual.http://www.thl.fi/publications/monica/index.html. Accessed 26 Feb 2015.
- 20.Hansen ES. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/2. Shared risk factors for cancer and atherosclerosis–a review of the epidemiological evidence. Mutat Res. 1990;239(3):163–79.Google Scholar
- 25.Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332(10):635–41.PubMedCrossRefGoogle Scholar
- 27.Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematol Am Soc Hematol Educ Program. 2007;2007(1):127–35.Google Scholar
- 36.Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12.PubMedCrossRefGoogle Scholar